Segall Bryant & Hamill LLC Takes Position in Regeneron Pharmaceuticals, Inc. $REGN

Segall Bryant & Hamill LLC acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 1,311 shares of the biopharmaceutical company’s stock, valued at approximately $1,016,000.

Other institutional investors have also recently modified their holdings of the company. WPG Advisers LLC lifted its stake in shares of Regeneron Pharmaceuticals by 312.5% in the fourth quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 25 shares during the period. SHP Wealth Management acquired a new stake in Regeneron Pharmaceuticals in the fourth quarter valued at $26,000. Western Wealth Management LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter worth $26,000. Titan Wealth CI Ltd acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $29,000. Finally, Kemnay Advisory Services Inc. acquired a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $31,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 200 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The shares were sold at an average price of $650.15, for a total value of $130,030.00. Following the transaction, the director owned 17,303 shares in the company, valued at approximately $11,249,545.45. This represents a 1.14% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.97% of the stock is currently owned by company insiders.

Key Headlines Impacting Regeneron Pharmaceuticals

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Analysts and quantitative models point to improving earnings-estimate revisions, suggesting potential near-term upside for REGN. Regeneron is also being highlighted as a relatively attractive value stock within the biomedical and genetics sector. Surging Earnings Estimates Signal Upside for Regeneron Stock
• Positive Sentiment: Guggenheim raised its price target for Regeneron to $1,030, a notably bullish view that reflects confidence in the company’s earnings power and long-term pipeline. Citigroup also adjusted its target to $740. Guggenheim Increases Regeneron Price Target
• Neutral Sentiment: Articles comparing REGN with Incyte (INCY) frame the decision as a value-investing choice rather than announcing a new company-specific development. Regeneron’s valuation remains supported by strong profitability and its previously reported quarterly earnings and revenue beat. REGN or INCY: Which Is the Better Value Stock Right Now?
• Negative Sentiment: Multiple law firms announced or promoted a securities class action alleging that Regeneron and certain executives misled investors about the prospects and protocol of the Phase 3 Fianlimab-Libtayo melanoma trial. The trial’s failure reportedly contributed to a sharp prior selloff and an approximately $11 billion market-capitalization loss. Investors in the August 1, 2025–May 15, 2026 class period face a September 14, 2026 lead-plaintiff deadline. These announcements largely repeat the same allegations, but they reinforce litigation and reputational overhang. Regeneron Clinical Trials Lead to Securities Fraud Class Action

Analyst Ratings Changes

A number of equities analysts have recently weighed in on REGN shares. Benchmark raised Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $185.00 price target for the company in a report on Tuesday, July 7th. Leerink Partners reaffirmed a “market perform” rating and set a $641.00 price target (down from $792.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, May 18th. Truist Financial boosted their target price on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, June 24th. Finally, Barclays decreased their target price on shares of Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. One research analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and ten have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $797.75.

Regeneron Pharmaceuticals Stock Up 1.0%

REGN stock opened at $768.58 on Thursday. The firm’s 50-day simple moving average is $650.88 and its 200 day simple moving average is $711.54. The stock has a market cap of $81.25 billion, a PE ratio of 19.00, a price-to-earnings-growth ratio of 1.34 and a beta of 0.22. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $541.00 and a fifty-two week high of $821.11.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm had revenue of $4.29 billion during the quarter, compared to analyst estimates of $3.82 billion. During the same quarter in the prior year, the firm posted $12.81 EPS. Regeneron Pharmaceuticals’s revenue was up 16.7% compared to the same quarter last year. As a group, sell-side analysts predict that Regeneron Pharmaceuticals, Inc. will post 43.11 EPS for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, August 31st. Shareholders of record on Tuesday, August 18th will be paid a dividend of $0.94 per share. This represents a $3.76 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend is Tuesday, August 18th. Regeneron Pharmaceuticals’s payout ratio is 9.29%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.